FDA seeks public input on clinical trial design for ibogaine drug products

The U.S. Food and Drug Administration has launched a request for public input on clinical trial designs for the psychedelic drug ibogaine, marking a major regulatory step. Spurred by a $50 million executive order from President Donald Trump, federal agencies are advancing trials to treat opioid addiction and PTSD. While a booming, unregulated $20,000-per-stay ibogaine retreat industry has emerged in Mexico, experts warn that the Schedule I substance carries severe, potentially fatal cardiac risks.

FDA request for input on ibogaine trial designs

• ▪The Food and Drug Administration is seeking public input on specific ibogaine trial parameters, including a proposed starting dose not exceeding 10 mg/kg and the use of small, sequential dose-ascending groups.
• ▪The U.S. Food and Drug Administration announced a request for information on October 5, 2026, seeking public feedback on early-phase clinical trial designs for ibogaine drug products.
• ▪The Food and Drug Administration opened a public docket seeking feedback on ibogaine trial protocol elements, including dose selection, patient eligibility, safety monitoring, and study-stopping rules, with comments closing on November 20, 2026.

Psychedelic safety standards

• ▪The Food and Drug Administration previously issued finalized guidance in July 2026 titled "Psychedelic Drugs: Considerations for Clinical Investigations" to assist sponsors developing psychedelic drugs.
• ▪Experts and veterans have called for strict safety standards on psychedelic treatments.

Executive order on psychedelic medicine research

• ▪President Donald Trump's April 2026 executive order dedicated $50 million in federal funding to support ibogaine research.
• ▪President Donald Trump issued an executive order in April 2026 titled "Accelerating Medical Treatments for Serious Mental Illness," which directed federal agencies to accelerate research into psychedelic medicine.

Federal funding for ibogaine research

• ▪The Department of Health and Human Services is funding early-stage clinical trials of ibogaine through the Advanced Research Projects Agency for Health to examine safety and efficacy in treating post-traumatic stress disorder alongside opioid addiction.
• ▪The National Institute on Drug Abuse is funding research on ibogaine for the potential treatment of opioid use disorder in adults.
• ▪The Department of Health and Human Services is prioritizing adults with post-traumatic stress disorder as one of two initial populations for federally supported ibogaine research.

Properties, risks, and legal status of ibogaine

• ▪Ibogaine carries severe health risks, including life-threatening irregular heart rhythms, potential brain toxicity, and potentially fatal cardiac complications.
• ▪Ibogaine is classified as an illegal Schedule I controlled substance under United States law and is unavailable for medical use in the country.
• ▪The effects of high-dose ibogaine treatments can continue for more than 24 hours, leaving patients in a waking, dreamlike state.

Ibogaine clinics and medical tourism in Mexico

• ▪The New York Times identified at least 40 clinics and wellness centers in Mexico offering ibogaine treatments in August 2026, compared with almost none a decade earlier.
• ▪Americans are traveling to Mexico and other Latin American countries like Costa Rica for ibogaine treatments, paying between $5,000 and $20,000 per stay.
• ▪Ibogaine clinics in Mexico, such as Beond Ibogaine in Cancún and Ibogaine Clinic in Playa del Carmen, market treatments for addiction, burnout, personal growth, and performance optimization.

Debatable claims

• ▪The potential therapeutic benefits of ibogaine justify its severe cardiac risks
• ▪The federal government should fund clinical trials for ibogaine
• ▪The Schedule I controlled substance classification of ibogaine is justified